-->

Company Registry

Abcombi Biosciences Inc
Profile last edited on: 6/12/2017

Rethinking current vaccine paradigms to deliver “smarter” vaccine solutions
Year Founded
2015
First SBIR Year
2016
Latest SBIR Award
2021
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

303 Furnas Hall
Buffalo, NY 14260
   (919) 619-6772
   N/A
   www.abcombibio.com
Multiple Locations:   
Congressional District:   26
County:   Erie

Public Profile

Abcombi Biosciences is a pre-clinical vaccine and therapeutic development company addressing delivery of “smarter” vaccine and anti-infective solutions. Based in Buffalo but having labs space in Johnson & Johnson’s incubator, JLABs, Toronto. the firm has already developed key technologies and analytical strategies to facilitate our unique protection strategies: The firm has developed a novel biofilm model that mimics the natural progression of disease for colonizing bacteria such Streptococcus pneumoniae and Staphylococcus aureus. The plan is toengage ioinformatics in conjunction with our biofilm model to identify antigens associated with specific stages of disease progression. The firm also has crated a novel formulation strategy that removes the need for complex chemistry to produce polysaccharide conjugate vaccines and a broad RNA-based therapy for treating influenza infections.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  Charles Houston Jones -- CEO

  Andrew Hill --

  Chris Kilgore -- Chief Operating Officer

  Jonathan Lovell -- Founder

  Blaine Pfeifer --

SBIR firms in the news

There are no news available.